Nephros (NEPH) Competitors

$3.68 +0.55 (+17.57%)

Closing price 04:00 PM Eastern

Extended Trading

$3.58 -0.11 (-2.85%)

As of 04:40 PM Eastern

NEPH vs. NNOX, EDAP, APYX, HSDT, and TMCI

Should you buy Nephros stock or one of its competitors? MarketBeat compares Nephros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nephros include Nano-X Imaging (NNOX), Edap Tms (EDAP), Apyx Medical (APYX), Solana (HSDT), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry.

How does Nephros compare to Nano-X Imaging?

Nephros (NASDAQ:NEPH) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Nephros has a net margin of 4.06% compared to Nano-X Imaging's net margin of -790.87%. Nephros' return on equity of 7.66% beat Nano-X Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Nano-X Imaging	-790.87%	-64.65%	-57.27%

Nephros has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

In the previous week, Nano-X Imaging had 2 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Nano-X Imaging and 1 mentions for Nephros. Nano-X Imaging's average media sentiment score of 0.79 beat Nephros' score of 0.77 indicating that Nano-X Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nano-X Imaging	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.1% of Nephros shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nephros has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$19.12M	2.09	$1.19M	$0.07	52.57
Nano-X Imaging	$13.02M	9.09	-$75.02M	-$1.59	N/A

Nephros currently has a consensus price target of $6.00, indicating a potential upside of 63.04%. Nano-X Imaging has a consensus price target of $5.00, indicating a potential upside of 194.12%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, analysts clearly believe Nano-X Imaging is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nano-X Imaging	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	3 Strong Buy rating(s)	2.83

Summary

Nephros beats Nano-X Imaging on 10 of the 16 factors compared between the two stocks.

How does Nephros compare to Edap Tms?

Edap Tms (NASDAQ:EDAP) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Nephros has a net margin of 4.06% compared to Edap Tms' net margin of -41.47%. Nephros' return on equity of 7.66% beat Edap Tms' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edap Tms	-41.47%	-137.61%	-40.62%
Nephros	4.06%	7.66%	5.86%

In the previous week, Edap Tms had 10 more articles in the media than Nephros. MarketBeat recorded 11 mentions for Edap Tms and 1 mentions for Nephros. Nephros' average media sentiment score of 0.77 beat Edap Tms' score of 0.73 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edap Tms	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros has lower revenue, but higher earnings than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edap Tms	$70.53M	2.35	-$29.25M	-$0.81	N/A
Nephros	$19.12M	2.09	$1.19M	$0.07	52.57

Edap Tms presently has a consensus target price of $6.00, suggesting a potential upside of 35.75%. Nephros has a consensus target price of $6.00, suggesting a potential upside of 63.04%. Given Nephros' stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Edap Tms.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edap Tms	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Edap Tms has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market. Comparatively, Nephros has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

62.7% of Edap Tms shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 0.2% of Edap Tms shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Nephros beats Edap Tms on 11 of the 15 factors compared between the two stocks.

How does Nephros compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Nephros has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$55.90M	2.90	-$11.21M	-$0.22	N/A
Nephros	$19.12M	2.09	$1.19M	$0.07	52.57

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nephros has a net margin of 4.06% compared to Apyx Medical's net margin of -16.40%. Nephros' return on equity of 7.66% beat Apyx Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-16.40%	-88.47%	-14.94%
Nephros	4.06%	7.66%	5.86%

In the previous week, Apyx Medical had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for Apyx Medical and 1 mentions for Nephros. Nephros' average media sentiment score of 0.77 beat Apyx Medical's score of 0.38 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apyx Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apyx Medical presently has a consensus target price of $6.50, suggesting a potential upside of 67.96%. Nephros has a consensus target price of $6.00, suggesting a potential upside of 63.04%. Given Apyx Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Apyx Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Apyx Medical has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Nephros has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Summary

Apyx Medical beats Nephros on 9 of the 17 factors compared between the two stocks.

How does Nephros compare to Solana?

Solana (NASDAQ:HSDT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Solana has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Nephros has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Nephros has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02M	19.88	-$40.89M	-$109.67	N/A
Nephros	$19.12M	2.09	$1.19M	$0.07	52.57

In the previous week, Solana had 4 more articles in the media than Nephros. MarketBeat recorded 5 mentions for Solana and 1 mentions for Nephros. Nephros' average media sentiment score of 0.77 beat Solana's score of -0.19 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solana	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros has a net margin of 4.06% compared to Solana's net margin of -1,427.15%. Nephros' return on equity of 7.66% beat Solana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-115.56%	-22.67%
Nephros	4.06%	7.66%	5.86%

Solana presently has a consensus price target of $3.50, suggesting a potential upside of 60.55%. Nephros has a consensus price target of $6.00, suggesting a potential upside of 63.04%. Given Nephros' higher possible upside, analysts plainly believe Nephros is more favorable than Solana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

18.6% of Solana shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 14.4% of Solana shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nephros beats Solana on 11 of the 15 factors compared between the two stocks.

How does Nephros compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Treace Medical Concepts currently has a consensus price target of $4.77, indicating a potential upside of 73.45%. Nephros has a consensus price target of $6.00, indicating a potential upside of 63.04%. Given Treace Medical Concepts' higher probable upside, analysts plainly believe Treace Medical Concepts is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Treace Medical Concepts had 5 more articles in the media than Nephros. MarketBeat recorded 6 mentions for Treace Medical Concepts and 1 mentions for Nephros. Treace Medical Concepts' average media sentiment score of 1.40 beat Nephros' score of 0.77 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros has a net margin of 4.06% compared to Treace Medical Concepts' net margin of -29.44%. Nephros' return on equity of 7.66% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
Nephros	4.06%	7.66%	5.86%

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Treace Medical Concepts has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Nephros has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Nephros has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$207.32M	0.86	-$59M	-$0.97	N/A
Nephros	$19.12M	2.09	$1.19M	$0.07	52.57

Summary

Nephros beats Treace Medical Concepts on 9 of the 15 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.95M	$8.23B	$6.24B	$12.22B
Dividend Yield	N/A	2.54%	2.80%	5.30%
P/E Ratio	52.58	16.00	20.66	25.25
Price / Sales	2.09	8.15	546.68	70.73
Price / Cash	24.95	16.74	27.48	37.27
Price / Book	3.83	3.58	9.67	6.63
Net Income	$1.19M	$224.05M	$3.56B	$335.32M
7 Day Performance	24.75%	-2.48%	-1.91%	-1.83%
1 Month Performance	24.75%	-3.08%	-2.66%	-1.16%
1 Year Performance	70.37%	1.07%	31.17%	28.31%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	2.8419 of 5 stars	$3.68 +17.6%	$6.00 +63.0%	+44.9%	$39.95M	$19.12M	52.58	30	Gap Up
NNOX Nano-X Imaging	3.3498 of 5 stars	$1.79 -4.3%	$5.00 +179.3%	-69.3%	$130.13M	$13.02M	N/A	190
EDAP Edap Tms	3.9724 of 5 stars	$3.45 +3.3%	$6.00 +73.9%	+136.9%	$125.19M	$70.53M	N/A	230	Gap Up
APYX Apyx Medical	2.3694 of 5 stars	$2.79 -2.1%	$6.50 +133.0%	+183.2%	$119.21M	$52.84M	N/A	270
HSDT Solana	3.5009 of 5 stars	$2.16 flat	$3.50 +62.0%	-98.9%	$118.56M	$6.02M	N/A	30	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. NNOX, EDAP, APYX, HSDT, and TMCI

How does Nephros compare to Nano-X Imaging?

Summary

How does Nephros compare to Edap Tms?

Summary

How does Nephros compare to Apyx Medical?

Summary

How does Nephros compare to Solana?

Summary

How does Nephros compare to Treace Medical Concepts?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. NNOX, EDAP, APYX, HSDT, and TMCI

How does Nephros compare to Nano-X Imaging?

Is NEPH or NNOX more profitable?

Which has more volatility and risk, NEPH or NNOX?

Does the media refer more to NEPH or NNOX?

Do institutionals & insiders believe in NEPH or NNOX?

Which has stronger earnings and valuation, NEPH or NNOX?

Do analysts rate NEPH or NNOX?

Summary

How does Nephros compare to Edap Tms?

Is EDAP or NEPH more profitable?

Does the media prefer EDAP or NEPH?

Which has higher earnings & valuation, EDAP or NEPH?

Do analysts prefer EDAP or NEPH?

Which has more volatility and risk, EDAP or NEPH?

Do institutionals and insiders hold more shares of EDAP or NEPH?

Summary

How does Nephros compare to Apyx Medical?

Which has stronger earnings & valuation, APYX or NEPH?

Do institutionals & insiders have more ownership in APYX or NEPH?

Is APYX or NEPH more profitable?

Does the media favor APYX or NEPH?

Do analysts prefer APYX or NEPH?

Which has more volatility & risk, APYX or NEPH?

Summary

How does Nephros compare to Solana?

Which has more volatility and risk, HSDT or NEPH?

Which has better valuation & earnings, HSDT or NEPH?

Does the media favor HSDT or NEPH?

Is HSDT or NEPH more profitable?

Do analysts prefer HSDT or NEPH?

Do institutionals and insiders have more ownership in HSDT or NEPH?

Summary

How does Nephros compare to Treace Medical Concepts?

Do analysts prefer TMCI or NEPH?

Does the media favor TMCI or NEPH?

Is TMCI or NEPH more profitable?

Do institutionals and insiders hold more shares of TMCI or NEPH?

Which has more volatility and risk, TMCI or NEPH?

Which has better earnings & valuation, TMCI or NEPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools